tiprankstipranks
Advertisement
Advertisement
Phil Nadeau Reiterates Buy on Enliven, Citing Strong ELVN-001 Early Data, Clear Pivotal Path, and Solid Cash Runway to 2029
PremiumRatingsPhil Nadeau Reiterates Buy on Enliven, Citing Strong ELVN-001 Early Data, Clear Pivotal Path, and Solid Cash Runway to 2029
14d ago
Needham’s Boris Peaker Reiterates Buy on Enliven, Citing Strong ELVN-001 Efficacy in CML and Pivotal Phase 3 ENABLE-2 Catalyst Pathway
Premium
Ratings
Needham’s Boris Peaker Reiterates Buy on Enliven, Citing Strong ELVN-001 Efficacy in CML and Pivotal Phase 3 ENABLE-2 Catalyst Pathway
15d ago
Enliven reports Q1 EPS (38c) vs. (57c) last year
Premium
The Fly
Enliven reports Q1 EPS (38c) vs. (57c) last year
15d ago
Enliven Therapeutics: Compelling ELVN-001 CML Data, Strong Cash Runway Support Buy Rating
PremiumRatingsEnliven Therapeutics: Compelling ELVN-001 CML Data, Strong Cash Runway Support Buy Rating
3M ago
Enliven reports Q4 EPS (48c), consensus (47c)
Premium
The Fly
Enliven reports Q4 EPS (48c), consensus (47c)
3M ago
Enliven Therapeutics: Robust ELVN-001 CML Data, Clear Pivotal Path, and Solid Cash Runway Support Buy Rating
Premium
Ratings
Enliven Therapeutics: Robust ELVN-001 CML Data, Clear Pivotal Path, and Solid Cash Runway Support Buy Rating
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100